Roche Update Should Raise Questions About Next Year's Growth Trajectory
Dow Jones10-22
0905 GMT - Roche Holding's underlying sales trends look disappointing and the Swiss drugmaker's third-quarter update should raise questions about its growth trajectory next year, Jefferies analysts say in a research note. The company's eye drug Vabysmo, cancer therapy Kadcyla and asthma and allergy medicine Xolair are all facing pressure, Jefferies says. It is hard to see more than low-single-digit growth in 2027 given current trends, even with new breast-cancer drug giredestrant launching, the analysts say. For 2026, the company is guiding for sales growth excluding currency movements in the mid-single-digit range. Shares fall 0.7%.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments